PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results